BLASUBCUTANEOUSINJECTABLE
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
4/8 — Partial
LEQEMBI IQLIK (lecanemab-irmb) by Eisai is amyloid beta-directed antibody interactions [moa]. Approved for amyloid beta-directed antibody [epc]. First approved in 2025.
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEQEMBI IQLIK (lecanemab-irmb) is a subcutaneous formulation of lecanemab, a monoclonal antibody targeting amyloid beta for early Alzheimer's disease. It works by binding to amyloid beta protofibrils to reduce cognitive decline in patients with mild cognitive impairment or mild dementia due to Alzheimer's disease. This subcutaneous version expands accessibility beyond the original intravenous formulation.
Growth
Early-stage launch with recent FDA approval; commercial team expansion expected as market adoption accelerates and subcutaneous convenience drives patient enrollment.
Mechanism of Action
Amyloid Beta-directed Antibody Interactions
Pharmacologic Class:
Amyloid Beta-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LEQEMBI IQLIK represents a high-visibility neurology launch with strong clinical impact and significant commercial upside in the growing Alzheimer's market. Professionals joining this product team will be part of a transformative wave in CNS disease-modifying therapy, with opportunities spanning field sales, market access, and brand management as market adoption accelerates.
Brand Manager
Worked on LEQEMBI IQLIK at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.